- Diagnos (ADK) has formed a partnership in Saudi Arabia with Magrabi Hospitals & Centres to screen diabetic patients
- Magrabi will be working with Diagnos to help assist screening availability to more diabetic patients using Diagnos AI technology
- By placing the project near the patient base, CARA is able to dramatically increase patient volume
- After carrying out this project, the plan is to offer the screening to all Magrabi hospitals in the Kingdom of Saudia Arabia, Middle East and Africa
- Diagnos is currently down 4.00 per cent to C$0.72 per share
Diagnos (ADK) has formed a partnership in Saudi Arabia with Magrabi Hospitals & Centres to screen diabetic patients.
Founded in 1955, Magrabi Hospitals & Centres gives more than one million patients eye care annually.
In addition, Diagnos is reopening five screening clinics at multiple locations of Magrabi located in Riyadh. All thanks to their new Saudi Arabia business partner, Kanhoor medical.
To date, Magrabi operates in 30 locations including but not limited to Yemen, United Arab Emirates, Qatar, Egypt, and Saudi Arabia.
Diagnos, is based out of Brossard, Québec, and uses an Artificial Intelligence (AI) CARA (Computer Assisted Retina Analysis), to assist healthcare professionals in the spotting of critical health issues.
Moreover, Magrabi will be working with Diagnos to help asses more diabetic patients using Diagnos AI technology.
In placing the project near the patient base, CARA is therefore able to dramatically increase patient volume.
Most importantly, the plan is to offer the screening to all Magrabi hospitals in the Kingdom of Saudia Arabia, Middle East and Africa.
During the announcement, Vice-President of Sales for Diagnos, Yves-Stéphane Couture said he is eagerly awaiting the partnership.
“This commercial project is establishing the foundation of a partnership between Magrabi, Kanhoor and Diagnos to deploy in the remaining 22 clinics in Saudi Arabia in the second half of 2021,” he said
Over the part five years, the Diagnos stock has been declining. However, over the past year the company’s share price has slowly started to climb back up up.
Diagnos is currently down 4.00 per cent with a price of C$0.72 per share at 4 PM EST.
